Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma

Summary: Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-i...

Full description

Bibliographic Details
Main Authors:	Nazanin Tatari, William T. Maich, Sabra K. Salim, Dillon Mckenna, Chitra Venugopal, Sheila Singh
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	STAR Protocols
Subjects:	Cancer Immunology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666166720301611

id	doaj-915efde6842243eb88b230ca0e0e28fc
record_format	Article
spelling	doaj-915efde6842243eb88b230ca0e0e28fc2020-12-21T04:49:00ZengElsevierSTAR Protocols2666-16672020-12-0113100174Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of GlioblastomaNazanin Tatari0William T. Maich1Sabra K. Salim2Dillon Mckenna3Chitra Venugopal4Sheila Singh5McMaster Stem Cell and Cancer Research Institute, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, CanadaMcMaster Stem Cell and Cancer Research Institute, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, CanadaMcMaster Stem Cell and Cancer Research Institute, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, CanadaDepartment of Surgery, McMaster University, Hamilton, ON L8S 4L8, CanadaDepartment of Surgery, McMaster University, Hamilton, ON L8S 4L8, CanadaMcMaster Stem Cell and Cancer Research Institute, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada; Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada; Corresponding authorSummary: Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-initiating cells. This protocol shows how to isolate peripheral blood mononuclear cells from healthy donors and generate CAR T cells for the antigens of interest, and how to intracranially inject the CAR T cells into a patient-derived xenograft mouse model of GBM.For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).http://www.sciencedirect.com/science/article/pii/S2666166720301611CancerImmunology
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Nazanin Tatari William T. Maich Sabra K. Salim Dillon Mckenna Chitra Venugopal Sheila Singh
spellingShingle	Nazanin Tatari William T. Maich Sabra K. Salim Dillon Mckenna Chitra Venugopal Sheila Singh Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma STAR Protocols Cancer Immunology
author_facet	Nazanin Tatari William T. Maich Sabra K. Salim Dillon Mckenna Chitra Venugopal Sheila Singh
author_sort	Nazanin Tatari
title	Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma
title_short	Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma
title_full	Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma
title_fullStr	Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma
title_full_unstemmed	Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma
title_sort	preclinical testing of car t cells in a patient-derived xenograft model of glioblastoma
publisher	Elsevier
series	STAR Protocols
issn	2666-1667
publishDate	2020-12-01
description	Summary: Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-initiating cells. This protocol shows how to isolate peripheral blood mononuclear cells from healthy donors and generate CAR T cells for the antigens of interest, and how to intracranially inject the CAR T cells into a patient-derived xenograft mouse model of GBM.For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).
topic	Cancer Immunology
url	http://www.sciencedirect.com/science/article/pii/S2666166720301611
work_keys_str_mv	AT nazanintatari preclinicaltestingofcartcellsinapatientderivedxenograftmodelofglioblastoma AT williamtmaich preclinicaltestingofcartcellsinapatientderivedxenograftmodelofglioblastoma AT sabraksalim preclinicaltestingofcartcellsinapatientderivedxenograftmodelofglioblastoma AT dillonmckenna preclinicaltestingofcartcellsinapatientderivedxenograftmodelofglioblastoma AT chitravenugopal preclinicaltestingofcartcellsinapatientderivedxenograftmodelofglioblastoma AT sheilasingh preclinicaltestingofcartcellsinapatientderivedxenograftmodelofglioblastoma
_version_	1724375502554136576

Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma

Similar Items